[Endocrine changes in gestagen treatment in a patient with scleroderma diffusa].
In a male patient, treated with gestagens and corticosteroids for diffuse scleroderma, endocrine alterations over two years are followed. A decrease in gonadotrophin plasma levels and an increase of prolactin is observed. Levels of testosterone, DHEA, and 17-alpha-hydroxyprogesterone are lowered, while those of estradiol and androstenedione remain unchanged. The alterations may be explained by a suppression of pituitary function and following decrease of testicular (and adrenal) steroid secretion.
D000328:Adult; D000735:Androstenedione / Q000097:blood; D003687:Dehydroepiandrosterone / Q000097:blood; D004958:Estradiol / Q000097:blood; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D010908:Pituitary Hormones, Anterior / Q000097:blood; D011374:Progesterone / Q000627:therapeutic use; D045167:Progesterone Congeners / Q000627:therapeutic use*; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000503:physiopathology; D013739:Testosterone / Q000097:blood
D010908:Pituitary Hormones, Anterior; D045167:Progesterone Congeners; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D011374:Progesterone; D004958:Estradiol; D008775:Methylprednisolone
Endokrine Verlaufsbeobachtung der Gestagenbehandlung bei einem Patienten mit Sclerodermia diffusa.